AI Leadership: Dual Awards Crowned | The Path to Health Shines at the 2026 Future Healthcare & Pharmaceutical Top 100 Conference
On May 19, the "2026 Future Healthcare & Pharmaceutical Top 100 Conference," organized by Artery Network, was successfully held in Shanghai.
The 2026 Future Healthcare & Pharmaceutical Top 100 Conference is one of the most influential annual events in China's healthcare industry. Under the theme of "Innovation, Trends, Collaboration," the conference focuses on cutting-edge areas such as brain-computer interfaces, medical AI, and digital marketing for pharmaceutical companies, bringing together prominent guests from government, academia, industry, investment circles, and clinical practice to pool industry expertise, foster innovative collaboration, and advance the high-quality development of China's healthcare sector.
As a leading enterprise in China's digital health and medical service platform sector, HealthyWay (2587.HK) actively participated in this conference, showcasing its innovative AI-driven technological concepts and commercial achievements at two core forums, and winning two prestigious industry awards. This fully demonstrates the company's strategic layout and pioneering practices in medical AI and digital marketing for pharmaceutical companies.
Three prominent guests attended both major forums.
Let's explore together how AI and digital marketing can break through current challenges.
At this conference, three key executives from HealthyWay participated in two major forums, where they comprehensively presented the company's cutting-edge insights and practical implementations in medical AI and digital marketing for pharmaceutical companies.
01
Medical AI and Large Model Application Development Forum
At the "Medical AI and Large Model Application Development Forum," Mr.Zhang Wanneng, Chairman of HealthyWay, delivered a keynote speech titled "From 'Capable of Dialogue' to 'Capable of Action: Intelligent Weight Management Reforms the Operational Framework of Healthcare Enterprises."
He emphasized that the most fundamental transformation in the AI era is the return of human-computer interaction to a minimalist chat interface, with intelligent agents set to reshape the entire sales, service, and management processes within healthcare enterprises.
Zhang Wanneng, Chairman of HealthyWay
HealthyWay has established a comprehensive product portfolio of three intelligent assistant solutions: "Akang" for management, "Ajian" for sales and service, and "Achuang" for development and innovation. These three assistants cover the entire enterprise operation chain, creating a collaborative workflow model where AI leads while humans support. HealthyWay has successfully transitioned from conversational AI to commercially viable action-oriented intelligent agents.
02
Pharmaceutical Companies Digital Marketing Forum
As a co-organizer of the "Pharmaceutical Companies 'Digital Marketing Forum" at this conference, HealthyWay played an active role in both organizing and co-developing the forum's content.
Keynote Speech: Charting a New Course
At the conference, Mr.Chen Jing, Executive Director and Senior Vice President of HealthyWay, delivered a keynote speech titled "Breaking Data Barriers, Building a Closed Growth Cycle: A New AI-Driven Ecosystem for Omnipresent Digital Marketing."
He emphasized, "Traffic is not an asset; only data that is usable, operable, and capable of forming a closed loop can be the sole driver of future growth."
Chen Jing, Executive Director and Senior Vice President of HealthyWay
The Health Initiative leverages AI-powered medical assistance as its core platform to achieve seamless integration of in-hospital and out-of-hospital data, foster integrated physician-patient collaboration, and establish a closed-loop data asset ecosystem. By building an AI-DOT+RWS ecosystem, it transforms data assets into tangible value for real-world research, enabling pharmaceutical marketing to evolve from selling individual drug boxes to delivering comprehensive, lifelong health management solutions.
Roundtable Forum: Discussing the Future
During the roundtable discussion session, Deng Jiayou, Assistant President and General Manager of the Pharmaceutical Cooperation Division at HealthyWay, engaged in a dialogue with representatives from leading pharmaceutical companies including Huahong Pharmaceutical, Yiling Pharmaceutical, and Chia Tai Tianqing.
He believes that the greatest challenge in the digital transformation of pharmaceutical companies lies not in technological issues but in mindset barriers. Compliance should not hinder growth but rather serve as a filter for viable growth opportunities. The platform should act as a bridge for compliance, pharmaceutical companies should provide specialized content, physicians should deliver medical services, and patients should benefit from health-related value—all working together to achieve mutual benefits and win-win outcomes.
Deng Jiayou, Assistant to the President of HealthyWay and General Manager of the Pharmaceutical Cooperation Division
The HealthyWay initiative adheres to compliance as its framework and academic rigor as its core, leveraging a mature platform to reduce trial-and-error costs while integrating physician education, patient management, and data-driven feedback across the entire healthcare chain, thereby enabling pharmaceutical companies to achieve stable, sustainable, and replicable growth.
The two major awards are truly well-deserved.
Its robust capabilities solidify its position as a benchmark in the industry.
After a decade of dedicated development, the Top 100 Future Healthcare Enterprises selection has become a highly credible and influential innovative benchmark in China's healthcare industry.
At the award ceremony of this conference, HealthyWay was honored with two prestigious awards—the "Top 50 Most Investment-Worthy Enterprises" and the "Top 50 Most Innovative Product Technologies" —for its outstanding overall strength and innovative products.
01
HealthyWay has been awarded the title of "One of the Top 50 Companies with the Highest Investment Value."
HealthyWay has established a unique platform-based competitive advantage by leveraging the dual core barriers of digital healthcare built upon 223 million registered users and 934,000 registered physicians.
The company specializes in offline healthcare scenarios, leveraging AI agents to enhance the entire medical service chain—from pre-diagnosis to diagnosis and post-diagnosis—continuously driving the advancement of the healthcare industry.
With robust revenue growth, a remarkable AI commercialization milestone exceeding 32 million yuan, and a clear strategic roadmap, HealthyWay was recognized as one of the "Top 50 Most Investment-Worthy Companies," demonstrating strong recognition from investors and the industry of its development potential.
02
Dr. Xiao An, the medical assistant at MedClaw, has been recognized.
The Top 50 Most Innovative Product Technologies
On the path to healthcare excellence, MedClaw's self-developed AI physician assistant Xiao An empowers comprehensive disease management through an AI-driven human-machine collaboration model, achieving dual benefits for patient medication adherence management (DOT) and real-world studies (RWS). Recognized for its groundbreaking technologies and clinical applications in enhancing patient compliance, optimizing clinical efficacy evaluation, and supporting pharmaceutical R&D decisions, it has been honored as one of the "Top 50 Most Innovative Product Technologies."
Other leading brands included JD Health, Alibaba Health, and Tencent Health have also been featured on this list.
Securing two prestigious awards consecutively fully demonstrates HealthyWay's strong core competitiveness in the digital healthcare sector and further solidifies its leading position as an industry benchmark.
The year 2026 marks a pivotal transition for the pharmaceutical and healthcare industry from the "traffic era" to the "data asset era." Through significant presentations at two major forums and the prestigious award recognition, HealthyWay has fully demonstrated its leading practices in medical AI and digital marketing for pharmaceutical companies during this conference.
In the future, HealthyWay will be driven by AI, embracing open technologies, open ecosystems, and open resources. It will collaborate with medical institutions, pharmaceutical companies, physicians, patients, and platforms to jointly build a professional and sustainable new digital health ecosystem, thereby promoting the high-quality development of China's healthcare industry.